"Channel blocker" from_date:2012

Calcium channel blockers for people with chronic kidney disease requiring dialysis. Calcium channel blockers (CCBs) are used to manage hypertension which is highly prevalent among people with chronic kidney disease (CKD). The treatment for hypertension is particularly challenging in people undergoing dialysis. To assess the benefits and harms of calcium channel blockers in patients with chronic

Using calcium-channel blockers during breastfeeding SPS - Specialist Pharmacy ServiceAbout Log in RegisterNHSGuidanceEventsPodcastsPlanningTrainingPublicationsTools SearchCOVID-19PGDsAdministeringCautions and contraindicationsDosingSwitchingMore Using calcium-channel blockers during breastfeedingPublished 2 June 2023Topics: Amlodipine · Cardiovascular system disorders · Diltiazem · 4 more Nifedipine and verapamil are the calcium-channel blockers of choice during breastfeeding. Recommendations apply to full term and healthy infants only.ContentsGeneral considerationsRecommendationChoice considerationsSpecific recommendationsNifedipineVerapamilAmlodipineDiltiazemFelodipinePatient InformationContact usAbout our recommendationsBibliographyGeneral considerationsIt is important to complete

Managing peripheral oedema caused by calcium channel blockers SPS - Specialist Pharmacy ServiceAbout Log in RegisterNHSGuidanceEventsPlanningTrainingPublications SearchHomeManaging peripheral oedema caused by calcium channel blockersPaula Russell, Principal Pharmacist, Regional Drug and Therapeutics Centre (Newcastle Upon Tyne) · Published 26 September 2022Topics: Adverse effects · Amlodipine · Cardiovascular system disorders · 6 more All calcium channel blockers may cause peripheral oedema. There are different treatment options and the incidence can be affected by different factors.ContentsAbout ankle oedemaSymptomsCauseFactors affecting incidenceDifferences in chemical classDoseDuration of actionEffect on blood pressureTreatment optionsNon-Pharmacological methodsDose adjustmentsSwitching to another

Calcium channel blockers You need to be logged in to see the full monograph.LoginUSE OF CALCIUM CHANNEL BLOCKERS IN PREGNANCYDate of issue: May 2023, Version: 2A corresponding patient information leaflet on USE OF CALCIUM CHANNEL BLOCKERS IN PREGNANCY is available.Calcium channel blockers (CCBs) (amlodipine, diltiazem, felodipine, lacidipine, lercanidipine, nicardipine, nifedipine, nimodipine

Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial The long-term relative risk of antihypertensive treatments with regard to mortality and morbidity is not well understood. To determine the long-term posttrial risk of primary and secondary outcomes among trial participants who were randomized to either a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor with up to 23 years of follow-up. This prespecified secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a multicenter randomized, double-blind, active-controlled clinical trial, followed up

The calcium channel blocker nimodipine inhibits spinal reflex pathways in humans. Voltage-sensitive calcium channels contribute to depolarization of both motor neurons and interneurons in animal studies, but less is known of their contribution to human motor control and whether blocking them has potential in future antispasmodic treatment in humans. Therefore, this study investigated the acute

Rationale and Design of a Randomized, Open-Label, Parallel-Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT-HT). Angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed as first- and second-line treatments for older Japanese patients

Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records. ADHD is a chronic neurodevelopmental disorder that significantly affects life outcomes, and current treatments often have adverse side effects, high abuse potential, and a 25% non-response rate , highlighting the need for new therapeutics. This study investigates amlodipine, an L-type calcium channel blocker, as a potential foundation for developing a novel ADHD treatment by integrating findings from animal models and human genetic data. Amlodipine reduced hyperactivity in SHR rats and decreased both hyperactivity and impulsivity in adgrl3.1-/- zebrafish. It also crosses the blood-brain barrier

Association of systemic calcium channel blockers use with visual field progression in a large real-world cohort from glaucoma clinics. To test the association between use of calcium channel blocker (CCB) medications and the rate of visual field (VF) progression in a large cohort of patients from five glaucoma clinics. Retrospective, longitudinal case-control study. Patients attending five

L-type calcium channel blocker increases VEGF concentrations in retinal cells and human serum. Vascular endothelial growth factor (VEGF) plays a key role in diabetic retinopathy (DR). Previously, we have reported an association between mutations in a gene coding for the L-type calcium channel subunit, VEGF and DR. L-type calcium channel blockers (LTCCBs) have been widely used as antihypertensive

Effects of calcium channel blockers on perioperative ischemic events in hypertensive patients with intracranial aneurysms undergoing neurointervention. Although calcium channel blockers (CCBs) are useful in stroke prevention, their specific role in preventing stroke in hypertensive patients with intracranial aneurysms undergoing endovascular stent placement remains unclear. We retrospectively

Hemoadsorption Therapy for Calcium Channel Blocker Overdose: A Case Report. Modern resin hemoadsorption/hemoperfusion for calcium channel blocker overdose is yet to be reported. The characteristics of calcium channel blockers make them unamenable to removal by hemodiafiltration or charcoal hemoperfusion; however, elimination, using styrene bead adsorption in an ex vivo model, has been

Dihydropyridine Calcium Channel Blockers and Kidney Outcomes. Early trials of dihydropyridine calcium channel blockers (DCCBs) suggest a detrimental effect on intraglomerular pressure and an association with albuminuria. We sought to evaluate the associations of DCCB initiation with albuminuria and kidney failure with replacement therapy (KFRT) and to determine whether renin-angiotensin system

REBEL Core Cast 109.0 – Na Channel Blocker Poisoning REBEL Core Cast 109.0 - Na Channel Blocker Poisoning - REBEL EM - Emergency Medicine BlogSkip to content * Home * Blog * COVID-19 * Submit a Post * CAST * REVIEWS * PREZ * CRIT * CME/CEH * CORE * About * About Us * Meet The Team * Friends of REBEL EM * REBEL Swag * Disclaimer Menu * Home * Blog * COVID-19 * Submit a Post * CAST * REVIEWS * PREZ * CRIT * CME/CEH * CORE * About * About Us * Meet The Team * Friends of REBEL EM * REBEL Swag * Disclaimer * September 27, 2023REBEL Core Cast 109.0 – Na Channel Blocker Poisoning * Written byAnand Swaminathan * REBEL Cast, REBEL Core * Medical Category:ToxicologyTake Home Points: * In the context of poisoning, a “wide QRS” is anything

Reversal of propofol-induced depression of the hypoxic ventilatory response by BK-channel blocker ENA-001: a randomized controlled trial. The use of anesthetics may result in depression of the hypoxic ventilatory response. Since there are no receptor-specific antagonists for most anesthetics, there is the need for agnostic respiratory stimulants, that increase respiratory drive irrespective

A computational model predicts sex-specific responses to calcium channel blockers in mammalian mesenteric vascular smooth muscle. The function of the smooth muscle cells lining the walls of mammalian systemic arteries and arterioles is to regulate the diameter of the vessels to control blood flow and blood pressure. Here, we describe an in silico model, which we call the 'Hernandez-Hernandez heightened sensitivity to commonly used Ca channel blockers compared to male. In summary, we present a new model framework to investigate the potential sex-specific impact of antihypertensive drugs.

Evaluating Provider and Pharmacy Discordance in Potential Calcium Channel Blocker-Loop Diuretic Prescribing Cascade. Prescribing cascades occur when a drug-induced adverse event is treated with a new medication. Identifying clinical scenarios in which prescribing cascades are more likely to occur may help determine ways to prevent prescribing cascades. To understand the extent to which discordant providers and discordant pharmacies contribute to the dihydropyridine calcium channel blocker (DH CCB)-loop diuretic prescribing cascade. A retrospective cohort study using Medicare Fee-For-Service data (2011-2018) of adults aged ≥ 66 years. Patients who initiated DH CCB with subsequent initiation of loop diuretic (DH CCB-loop diuretic dyad) within 90 days or patients who initiated angiotensin

Pharmacokinetics and Pharmacodynamics of Etripamil, an Intranasally Administered, Fast-Acting, Nondihydropyridine Calcium Channel Blocker. Etripamil, a fast-acting nondihydropyridine L-type calcium channel blocker, is under investigation for potential self-administration for the acute treatment of supraventricular tachyarrhythmias in a medically unsupervised setting. We report detailed

Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial. Clinical concerns exist about the potential proarrhythmic effects of the sodium channel blockers (SCBs) flecainide and propafenone in patients with cardiovascular disease. Sodium channel blockers were used to deliver early rhythm control (ERC) therapy in EAST-AFNET 4. We analysed

Association of Calcium Channel Blocker Use With Intradialytic Hypotension in Maintenance Hemodialysis. Calcium channel blockers (CCBs) are common antihypertensive agents among patients receiving hemodialysis (HD). Despite this, the association of CCBs with intradialytic hypotension (IDH), an important adverse outcome that is associated with cardiovascular morbidity and mortality, remains largely